Recent Posts

• TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
• Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
• TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
• TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
• TOLLYS : la phase clinique bientôt en vue (La Gazette du Laboratoire – Juillet 2022)